Sorafenib-induced erythema multiforme: three cases

Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato‐oncology clinic

“…The eruption appeared from 1 to 8 weeks after initiation of sorafenib, and common sites were the face, scalp, and trunk. Our literature search yielded 23 cases of sorafenib-induced erythema multiforme/erythema multiforme-like eruption, [10][11][12][13][14][15][16][17] and one case of toxic epidermal necrolysis due to sorafenib and tosufloxacin intake. 18 Mean interval from initiation of treatment to the appearance of the rash was 5.6 days (range [3][4][5][6][7][8][9][10][11][12][13][14][15].…”

Sorafenib-Induced Eruption Mimicking Erythema Multiforme

“…One previously reported patient was able to restart sorafenib without recurrence of the eruption, 2 but other patients have had recurrence of the eruption upon retreatment or have not been rechallenged. 3–6 Despite the clinical appearance of our patient, histopathologic changes were not consistent with EM, and sorafenib was restarted without further sequelae. Unlike other cases reported in the literature, the patients reported here and by Bilac et al 2 clinically represent EM-like eruptions with targetoid lesions, histopathology not diagnostic of EM, and successful reinitiation of sorafenib.…”

Sorafenib Induces Delayed-Onset Cutaneous Hypersensitivity: A Case Series

“…It suggests that there have been immunologic responses requiring time lag to be sensitized and to gain immunologic memory. 7 Second, the features of skin lesions support the involvement of type IV hypersensitivity reaction. Although our patients did not undergo biopsy, previous studies of sorafenib-induced EM have revealed CD8+ lymphocytes infiltration into the epidermis and necrotic keratinocytes.…”

“…There have been only a few reports of sorafenib-induced erythema multiforme (EM) so far. 4 , 5 , 6 , 7 However, other severe forms of delayed-type hypersensitivity reactions have not yet been reported. We herein report 3 cases of sorafenib-induced delayed-type cutaneous adverse reactions with their human leukocyte antigen (HLA) information.…”